Join the Clostridial Infection group to help and get support from people like you.
Clostridial Infection News
Related terms: Clostridium difficile-Associated Diarrhea, CDAD, CDI, Clostridium difficile Infection, Clostridium Infection, C. difficile, C. diff
Environmental Surfaces, Clinician Hands Play Role in C. Difficile Transmission in ICU
THURSDAY, April 10, 2025 – Environmental surfaces and health care personnel (HCP) hands play an important role in Clostridioides difficile transmission within health care facilities, according to a...
Diarrhea-Causing Bacteria Spreading Undetected Through Hospitals
MONDAY, April 7, 2025 – A notorious hospital-associated infection has been spreading through hospitals much more readily than people suspected, a new study says. The bacterium Clostridium difficile...
IBD Activity May Increase Risk for Clostridioides Difficile Infection
WEDNESDAY, March 5, 2025 – For patients with inflammatory bowel disease (IBD), risk factors associated with Clostridioides difficile infection (CDI) include recent diagnosis, corticosteroid usage,...
FDA Approves Vowst (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI
CAMBRIDGE, Mass. & HOBOKEN, N.J.--(BUSINESS WIRE)--Apr. 26, 2023-- Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced the U.S. Food and Drug Administration (FDA) ...
FDA Approves Rebyota (fecal microbiota, live-jslm) Microbiota-Based Live Biotherapeutic for the Prevention of Recurrence of Clostridioides Difficile Infection
Ferring’s novel first-in-class Rebyota is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic t...
FDA Approves Merck’s Dificid (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older
KENILWORTH, N.J.--(BUSINESS WIRE)-- Monday, January 27, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has...
CutisPharma Announces FDA Approval of Firvanq (vancomycin) for Treatment of Clostridium Difficile Associated Diarrhea and Staphylococcus Aureus Colitis
WILMINGTON, Mass. (Jan. 29, 2018) – CutisPharma announced today that the US Food and Drug Administration (FDA) has approved Firvanq (vancomycin hydrochloride) for oral solution, for the treatment of C...
FDA Approves Merck’s Zinplava (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection
KENILWORTH, N.J.--(BUSINESS WIRE) October 21, 2016 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Dificid for Clostridium difficile Infection
The U.S. Food and Drug Administration today approved Dificid (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD). Clostridium difficile (C. difficile) is a...